Next Article in Journal
Intake of Fat-Soluble Vitamins in the Belgian Population: Adequacy and Contribution of Foods, Fortified Foods and Supplements
Next Article in Special Issue
Developmental Outcomes at 24 Months of Age in Toddlers Supplemented with Arachidonic Acid and Docosahexaenoic Acid: Results of a Double Blind Randomized, Controlled Trial
Previous Article in Journal
Induced Aberrant Organisms with Novel Ability to Protect Intestinal Integrity from Inflammation in an Animal Model
Previous Article in Special Issue
Omega-3 Fatty Acids Supplementation Differentially Modulates the SDF-1/CXCR-4 Cell Homing Axis in Hypertensive and Normotensive Rats
Open AccessReview

Omega-3 Fatty Acids and Cardiovascular Disease: Summary of the 2016 Agency of Healthcare Research and Quality Evidence Review

1
Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI 02912, USA
2
Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA
*
Author to whom correspondence should be addressed.
Nutrients 2017, 9(8), 865; https://doi.org/10.3390/nu9080865
Received: 21 June 2017 / Revised: 3 August 2017 / Accepted: 4 August 2017 / Published: 11 August 2017
(This article belongs to the Special Issue Dietary Supplements)
We summarize the 2016 update of the 2004 Agency of Healthcare Research and Quality′s evidence review of omega-3 fatty acids and cardiovascular disease (CVD). The overall findings for the effects of marine oil supplements on intermediate CVD outcomes remain largely unchanged. There is high strength of evidence, based on numerous trials, of no significant effects of marine oils on systolic or diastolic blood pressures, but there are small, yet statistically significant increases in high density lipoprotein and low density lipoprotein cholesterol concentrations. The clinical significance of these small changes, particularly in combination, is unclear. The strongest effect of marine oils is on triglyceride concentrations. Across studies, this effect was dose-dependent and related to studies′ mean baseline triglyceride concentration. In observational studies, there is low strength of evidence that increased marine oil intake lowers ischemic stroke risk. Among randomized controlled trials and observational studies, there is evidence of variable strength of no association with increased marine oil intake and lower CVD event risk. Evidence regarding alpha-linolenic acid intake is sparser. There is moderate strength of evidence of no effect on blood pressure or lipoprotein concentrations and low strength of evidence of no association with coronary heart disease, atrial fibrillation and congestive heart failure. View Full-Text
Keywords: omega-3 fatty acids; alpha-linolenic acid; eicosapentaenoic acid; docosahexaenoic acid; marine oil; cardiovascular disease; blood pressure; high density lipoprotein; low density lipoprotein cholesterol; triglyceride; systematic review; meta-analysis omega-3 fatty acids; alpha-linolenic acid; eicosapentaenoic acid; docosahexaenoic acid; marine oil; cardiovascular disease; blood pressure; high density lipoprotein; low density lipoprotein cholesterol; triglyceride; systematic review; meta-analysis
Show Figures

Figure 1

MDPI and ACS Style

Balk, E.M.; Lichtenstein, A.H. Omega-3 Fatty Acids and Cardiovascular Disease: Summary of the 2016 Agency of Healthcare Research and Quality Evidence Review. Nutrients 2017, 9, 865.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop